At Informa Connect’s Copay, Reimbursement and Access Congress, Carl Schmid discusses the litigation filed by HIV+Hep, the DLC, and the DPAC in the U.S. District Court for DC challenging a federal rule that allows health insurers to avoid counting the value of drug manufacturer copay assistance toward patients’ out-of-pocket cost obligations in violation of the ACA definition of and regulations for cost-sharing.
Ensuring copay assistance counts for patients: A federal update
Carl Schmid discusses on a National Consumers League webinar current federal advocacy efforts to ensure that copay assistance for prescription drugs counts. This includes comments on two regulations, a congressional bill, and recent litigation initiated by HIV+Hep and two diabetes groups.
The social determinants affecting PrEP use and access
Carl Schmid and Dr. Milgram discusses the disparities in education and access to PrEP in the patient populations that need these medications the most.
Future opportunities to improve PrEP access and management
Carl Schmid and Lynne H. Milgram, MD, MBA, CPE, share ideas that can provide more substantial access to PrEP and battle unmet needs in PrEP management.
Press briefing on HIV+Hep, DLC, and DPAC vs. HHS
The HIV+Hepatitis Policy Insite, the Diabetes Leadership Council, and the Diabetes Patient Advocacy Coalition filed suit in the U.S. District Court for the District of Columbia challenging a federal rule that allows health insurers and pharmacy benefits managers to avoid counting drug manufacturer copay assistance toward patients’ out-of-pocket cost obligations. Due to increased deductibles and cost-sharing requirements, patients rely on copay assistance to help them afford their medications.